An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines
Qualia Life Sciences
Summary
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.
Description
Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period. Primary Outcome Measures: Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA) Secondary Outcome Measures: Remaining biomarkers in the Olink Target 48 Cytokine panel 36-Item Short Form Health Survey (SF-36) Frailty Index for Elders (FIFE) Depression Anxiety Stress Scale-21 (DASS-21) Side effect profile including: Number, type, severity, causali…
Eligibility
- Age range
- 45–79 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text. * Healthy adults 45 - 79 years of age Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. * Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these test…
Interventions
- Dietary SupplementQualia Senolytic
Qualia Senolytic manufactured by Qualia Life Science
Location
- Qualia Life SciencesCarlsbad, California